Tobira Therapeutics Inc. (TBRA): Pentwater Capital Management Reports New Position

Page 4 of 6 – SEC Filing
Item 1(a).
Name of Issuer:
Tobira Therapeutics, Inc
Item 1(b).
Address of Issuer’s Principal Executive Offices:
701 Gateway Boulevard, Suite 300
South San Francisco, CA 94080
Item 2(a).
Name of Person Filing:
Pentwater Capital Management, LP
Item 2(b).
Address of Principal Business Office, or if None, Residence:
614 Davis Street
Evanston, IL 60201
Item 2(c).
Citizenship:
Delaware, USA
Item 2(d).
Title of Class of Securities:
Common Stock, $0.001 par value
Item 2(e).
CUSIP Number: 88883P101
Item 3.
If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:
(a)
Broker or dealer registered under Section 15 of the Exchange Act.
(b)
Bank as defined in Section 3(a)(6) of the Exchange Act.
(c)
Insurance company as defined in Section 3(a)(19) of the Exchange Act.
(d)
Investment company registered under Section 8 of the Investment Company Act.
(e)
An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
(h)
A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;
(i)
A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;
(j)
Group, in accordance with

Follow Tobira Therapeutics Inc. (NASDAQ:TBRA)